Supplementary Table S2 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table S2 shows Dose limiting toxicity evaluation in dose escalation phase.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4406541255